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Simple Summary: Due to the COVID-19 pandemic, the oncology community was challenged with the
need to protect a vulnerable population from a potentially fatal infection without jeopardizing cancer
treatments. The impact of the crisis on the medical care of patients with oral cancer is largely unexplored.
This multicenter cohort study from Germany aims to assess the consequences of the COVID-19 pandemic
by comparing the healthcare of patients during the lockdown and post-lockdown periods in 2020 with the
corresponding periods in 2018/19. We found the closure of dental practices during lockdown to possibly
delay the diagnosis of oral cancer. Even if during this period no higher incidence of oral cancer was
observed, data point to potentially fatal consequences for longer periods of treatment delay.
Abstract: (1) Background: In response to the global COVID-19 pandemic, governmental measures
have been undertaken. The impact of the crisis on the healthcare of patients with cancer is largely
unexplored. This multicenter cohort study aimed to investigate a potential screening delay and its
consequences in patients with oral cancer (OC) during the pandemic. (2) Material and Methods: Data
of patients who were first diagnosed with OC during different periods were collected, especially in
terms of OC incidence, tumor stage/entity and time to intervention. The periods lockdown (LD)
(13 March–16 June 2020), post-lockdown (PLD) (17 June–1 November 2020), and the corresponding
equivalents in 2018/19 were differentiated and compared. (3) Results: There was no obvious trend
towards a higher incidence of OC or higher tumor stages, whereas a trend towards a shorter time
to intervention during the LD2020 could be observed. Subgroup analyses revealed an increased
incidence in OC within the PLD2020 in Mainz, which might be explained by the partial closure
of dental practices in this federal state during LD. (4) Conclusions: While there was no overall
higher incidence of OC, we found closure of practices during LD to possibly delay cancer diagnosis.
Therefore, measures must be taken to identify patients at risk and to ensure basic healthcare, especially
in the context of dental screening measures.
Keywords: COVID-19; SARS-CoV-2; oral cancer; oral malignant lesions; screening; precursor lesions;
lockdown; pandemic; head and neck cancer; HNSCC
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1. Introduction
The COVID-19 pandemic, with over 100 million people infected and 2 million deaths
so far [1], is often compared to other pandemics in world history. Between 1918 and 1920,
the Spanish flu—the worst influenza pandemic in history—killed between 27 and 50 mil-
lion people. However, what is the difference between these two pandemics? Coronaviruses
are ribonucleic acid (RNA) viruses of which some can infect humans causing a wide range
of diseases including gastrointestinal, respiratory, and central nervous system disorders.
SARS-CoV-2 was first described in China in late 2019 and is zoonotic in origin—bats have
been suggested to transmit the virus to humans [2]. Coronavirus disease is characterized by
an influenza-like illness including fever, cough, and myalgia; olfactory and taste disorders
were described frequently being a rare symptom in other respiratory virus diseases [3]. In
addition to the type of virus, external circumstances such as malnutrition, hygiene, access
to medical care, and the scientific standards of the time caused a much higher mortality rate.
Nevertheless, even about 100 years ago, there were calls for public health authorities to
work together with the medical profession and for a “public health authority organization”
to prevent the disease from spreading further [4]. Today, in the 21st century, such circum-
stances are hardly conceivable in industrialized countries. In addition to excellent national
medical care, state regulatory mechanisms ensure containment in pandemic situations.
To cope with the current COVID-19 pandemic, strategies of different escalation levels
are applied with the aim of containment, protection and risk reduction. A nationwide
“lockdown” was therefore declared on 16 March 2020, in Germany to prevent the health
system from being overloaded. Hospitals and practicing dentists equally had to adapt
to the state of the pandemic. Elective hospital admissions were stopped, non-emergency
operations were postponed and in some federal states, dentists were allowed to treat
emergencies only. This disruption of the regular care structure put oncological patients
with oral malignant lesions at increased risk, as screening examinations were suspended,
and urgent symptomatic cases were prioritized for diagnostic intervention. Kranz et al.
conducted a survey within the US and found a delay in receiving dental care in nearly half
of the population (46.7%) due to the COVID-19 pandemic [5]. Since oral precursor lesions
and oral malignant lesions are mainly detected by dentists during routine screening, it is
reasonable to assume that the nationwide lockdown and its restrictions on healthcare could
have led to failures in the screening of high-risk patients and consequently to an increase
in avoidable malignant lesions as well as a delayed diagnosis of oral tumors. Arduino et al.
found such a delay in diagnosis of oral cancer in the north Italian area of Turin due to the
SARS-CoV-2 outbreak [6]. Accordingly, not only an increased number of oral malignant
lesions after the lockdown but also the occurrence of higher tumor stages in the future
would have to be expected.
Oral cancer is among the 10 most common cancers in the world [7] and early diagnosis
significantly decreases morbidity and mortality [8]. About 5% of all malignant neoplasms
affect the oral cavity. Histologically, squamous cell carcinomas are present in 87% of cases,
and adenocarcinomas in about 4%. In Germany, men are affected more frequently and
on average three years earlier than women. Here, the incidence among women is about
4500 per year, among men more than 9000. According to the UICC tumor stage data, more
than one in four to five tumors in women is diagnosed at an early stage (0/I), while the
same number for men is every seventh. This also causes a significantly higher mortality
rate in men (9.7/100,000) when compared to women (3.5/100,000). The most important
risk factors for development of an oral malignant lesion are all forms of tobacco and alcohol
consumption. If both factors act together, the effect is considerably amplified [9]. Another
major risk factor is chronic infections with human papillomavirus (HPV) and the presence
of oral precursor lesions [10]. Since the prognosis for early-stage tumors is much better than
for advanced stages, early detection is of central importance and several early detection
methods and techniques have been advocated [11–14]. Even so, at present, there is no
specific biomarker to detect precursor lesions and early stages of oral cavity carcinoma. By
definition, a biomarker shows that a particular biological process or condition is present.
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In cancer diagnostics this means any measurable indicator used to determine the existence
of the disease. Since oral squamous cell carcinomas (OSCC) typically originates from
non-aberrant keratinocytes which are chronically exposed to a toxic stimulus leading to
dysplasia followed by invasive growth of carcinomatous cells, carcinogenesis consists
of a smooth transition that is sometimes hard to detect or to differentiate from benign
lesions [7]. Latest studies could show that increased levels of interleukin-8, subcutaneous
adipose tissue and pSTAT3 can be found in patients with OSCC [7,15]. Baran et al. found
an association between the melanoma-associated antigens A family and a high risk for
malignant transformation of leukoplakia [16]. Furthermore, recent evidence shows some
chromosomal changes that could be associated with OSCC. However, those findings are
still far beyond a specific biomarker that can be used in early detection of oral malignant
lesions. Most diagnostic measures still rely on surgical sampling which is an invasive
method that cannot be used as a general screening parameter for the population and
therefore requires a qualified specialist to identify and closely monitor and, if necessary,
initiate further diagnostics for patients at risk [17]. Since the growth of tumors is often
painless in the beginning without functional impairments, patients typically consult a
specialist with a delay of several weeks. The misinterpretation of lesions or their relevance
are supposed to be the main reasons for treatment delay in oral cancer. For this reason,
regular screening by the dentist is of crucial importance, especially for patients with risk
factors or predisposing diseases of the oral mucosa [9].
During the early period of the COVID-19 pandemic, especially between March and
June 2020, a reduced number of cancer diagnoses were reported by countries around the
globe [18–20]. Lai et al. stated a 66% reduction in chemotherapy administration across
eight hospitals in the UK [21], in Germany, radiation oncology institutions were able to
perform curative procedures with either unchanged or moderately decreased schedules,
whereas palliative or other radiotherapy procedures were often postponed [22].
A national population-based modeling study from the UK estimated a substantial
increase in the number of avoidable cancer deaths in the UK considering four tumor
types (breast cancer, colorectal cancer, lung cancer, and esophageal cancer). Based on
113,607 tumor cases, the group considered different reallocation scenarios that allowed the
assumption of more than 3000 additional deaths due to a diagnosis delay of 12 months over
a 5-year period [23]. Jacob et al. conducted a retrospective study on over 100,000 patients
in Germany newly diagnosed with cancer between May 2019 and May 2020. They found a
significant decrease of cancer diagnoses in general practices between March and May 2020
of up to 27.6%, and a similar trend in specialized practices with fewer initial diagnoses of
28.2–44.4%. This was pronounced among cancers of the skin and intrathoracic organs [24].
Another study analyzed cancer reporting by pathologists in North Rhine-Westphalia
(Germany) showing a relative reduction of 21% in cancer cases reported compared to the
previous year. Interestingly, the authors reported that there was no evidence of a “catch-up
effect” following this temporary decrease up until September 2020 [25]. Those findings
are in accordance to analyses from other European countries reporting a 44% reduction
in newly diagnosed cancer in Belgium during lockdown in April 2020 [26] and a weekly
increasing reduction of cancer diagnoses in the Netherlands of 9% up to 26% after the
beginning of the nationwide lockdown on March 15, 2020. This effect was especially
pronounced in skin cancer diagnoses showing a decrease of 44% up to 60% (16th through
19th calendar weeks) [25,26].
Reasons for this may be a reduced participation in screening programs, a delayed
detection of symptoms due to general practitioners’ practices being closed, or a delayed
treatment initiation even for patients already diagnosed with cancer due to reduced heath
care capacities [18]. A study by Riemann gave evidence that—in Germany—contacts
with the primary care physician dropped by up to 70% during the lockdown in 2020.
In addition, gastroenterologists experienced a massive cancellation of appointments for
elective examinations and a reduction in the number of appointments for preventive
examinations [27].
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Up to now, there is no therapeutic approach available to treat COVID-19. Interestingly,
nanomedicine-based strategies—also used in targeted cancer therapy—have been proposed
to be a promising option to both, treat viral infections and regulate the host’s immune
response [2]. Though, since the COVID-19 pandemic is still in progress and is likely
to reoccur in the future, there is a great need for evidence-based guidelines to ensure
healthcare, especially for patients with chronic diseases in compliance with infection
preventive measures.
Up to date, there has been no scientific evaluation on the impact of the COVID-
19 pandemic and its restrictions on healthcare on oral cancer detection. Therefore, this
study aimed to investigate the impact of the COVID-19 pandemic on patients with oral
malignant lesions
2. Materials and Methods
2.1. The COVID-19 Pandemic in Germany
Germany reported the first confirmed SARS-CoV-2 infections in January 2020, and by
mid-February 2020, multiple infection clusters had formed. To minimize the expansion of
clusters, the German disease and epidemic control advised by the Robert Koch Institute
(RKI) managed the outbreaks in the so-called protection stage from 13th of March 2020:
academic semesters were postponed, kindergartens were closed and dentists were, in some
parts of Germany, advised to either close their practice or to perform emergency treatments
only. Consequently, the Government declared a state of emergency, which was revoked
on 16 June 2020. On November 1st, restriction measurements were reimplemented due
to rising infection rates. The analytic periods in this study were chosen along this course
of the pandemic in Germany. After the incidence-triggered lockdown ended, patients
with postponed procedures were triaged and scheduled for therapy, including elective
procedures, according to their individual risk of infection and the urgency of the procedure,
in order to avoid the massive accumulation of scheduled procedures in subsequent months
and years.
2.2. Data Sources
Electronic medical records from the oral and maxillofacial surgery departments in
Mainz, Kiel and Berlin were queried using the ICD-10 diagnosis codes and those patients
who met the inclusion and exclusion criteria were identified. The three hospitals chosen are
located in three different federal states within Germany. In Mainz, located in Rhineland-
Palatinate, dental practices had to be partially closed for elective treatments during the first
lockdown, whereas in Berlin, federal state of Berlin, and Kiel, federal state of Schleswig-
Holstein, there were no closures required.
2.3. Inclusion and Exclusion Criteria
Patients with a histopathological confirmed diagnosis of oral cancer (ICD-10 code: C
00–C 14) who were initially diagnosed within the defined periods were included in the
study. The interval between 13 March 2020 and 16 June 2020 was defined as “lockdown”;
accordingly, the interval between 17 June 2020 and 1 November 2020 was considered the
“post-lockdown” period. The corresponding equivalents in 2018 and 2019 were used as
control groups.
Exclusion criteria were initial diagnoses outside the defined periods, extraoral cancer,
precursor lesions as well as extraoral manifested recurrences such as lymph node metas-
tases and distant metastases. Other factors that led to exclusion from the study were lack
of adherence to therapy (therapy delay, bias in time to intervention), death of the patient
within the period between the initial diagnosis and the start of therapy, the need for further
therapeutic interventions if the patient was at vital risk from other diseases (e.g., bypass
surgery for cardiovascular diseases) between the initial diagnosis and the start of therapy,
as well as dropout and lack of follow-up.
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2.4. Outcomes
The primary endpoint of the study was the incidence of patients with an initial diag-
nosis of oral cancer within the different periods. Furthermore, the cancer stage according
to the TNM-classification and the UICC-classification was recorded. Analysis of time to
the intervention was also defined as the primary endpoint. Various factors were eval-
uated for their independent association with an overall oral cancer diagnosis including
the specific type of diagnosis according to the ICD-10 classification, type of treatment
(surgery, radiotherapy, chemotherapy, immunotherapy, palliative therapy) and the form
of diagnosis (histopathological initial diagnosis after internal sampling and evaluation or
after collection by an external physician and sending to an external institute for processing;
external vs. internal).
2.5. Statistics
The statistical analyses were performed using SPSS version 27 for Macintosh (IBM,
Armonk, NY, USA). To analyze the differences between the measured values, normality
(Shapiro–Wilk) and homogeneity of variance tests (Levene Statistic) were performed at
first to check the conditions for the subsequent analysis. In case of not normally distributed
values, a Mann–Whitney test was used. To investigate whether the different tests lead to
similar results, McNemar tests were performed. A p-value ≤ 0.05 was termed significant.
3. Results
A total of 653 cases from three departments that met the inclusion criteria for this
study were analyzed. The different tumor entities according to ICD-10 coding, as well
as the tumor stages (TNM, UICC), kind of treatment modality, and kind of diagnosis are
shown in Tables S1–S5 and Figure S1 (Supplementary data).
3.1. Multicenter Data Analysis
The pooled analysis resulted in a total of 653 cases that met the inclusion criteria. A
total of 228 cases were identified for 2018, of which 77 were in the lockdown equivalent
(LD-E) period and 151 in the post-lockdown equivalent (PLD-E) period. The numbers
in the following years remained stable with a total of 210 cases in 2019 and 215 cases in
2020. The proportion between the different periods was also relatively stable at about
34–40% during the LD(E) period and 60–66% during the PLD(E) period. Regarding the
UICC stage ratio, a relatively stable distribution was seen with a proportion of 50% high
tumor stages in the LD(E) period while slightly fewer higher tumor stages were diagnosed
in the PLD period in 2020 compared to previous years (50.79% versus 59.18%). The analysis
showed a trend towards a shortened time to intervention during the 2020 LD period when
compared to previous years (22.99 ± 12.72 d versus 26.66 ± 14.29 d) while the time in
the 2020 PLD period remained stable compared to previous years (26.05 ± 13.84 d versus
26.14 ± 15.14 d). The multicenter data analysis confirmed the impression of a shorter time
to intervention by internal diagnosis, especially during the LD period in 2020 and the
equivalent period in 2018 and 2019 (LD 2020: p = 0.026, 21.05 ± 12.29 d vs. 28.79 ± 12.54 d;
LD 2018/2019: p = 0.026; 25.10 ± 15.21 d vs. 30.15 ± 11.37). Besides, a relatively shorter
time to intervention during LD 2020 could be observed, whereas values did not differ much
within the other periods (Figure 1).




Figure 1. Data sheet multicenter data evaluation: Distribution of patients with oral malignant lesions by different periods, 
distribution of tumor stages (T-classification, UICC-classification) and time to intervention during the different periods. 
Abbreviations: LD—lockdown; PLD—post-lockdown; LD-E—lockdown equivalent; PLD-E—post-lockdown equivalent; 
UICC—Union international contre le cancer. In (A) cancer diagnoses per year and period are displayed (in percent) show-
ing a stable distribution in both regards. In (B) the distribution of cancer cases by T-classifications divided into the different 
periods are displayed. Nearly no difference could be detected between LD and PLD, whereas a higher proportion of T4 
cancer could be seen during the PLD period in 2020 compared to the previous years. This effect is also reflected in the 
UICC-classification (C) and UICC-subclassification (D) with more stage IV cancer during the PLD period in 2020 (50.79% 
versus 59.18%). In (E) the time to intervention for the different time periods is displayed showing a trend towards a short-
ened time to intervention during the 2020 LD period compared to previous years while the time in the 2020 PLD period 
Figure 1. Data sheet multicenter data evaluation: Distribution of patients ith oral alignant lesions by different periods,
distribution of tumor stages (T-classification, UICC-classification) and time to intervention during the different periods.
Abbreviations: LD—lockdown; PLD—post-lockdown; LD-E—lockdown equivalent; PLD-E—post-lockdown equivalent;
UICC—Union international co tre le cancer. I (A) cancer diagnoses per ye r and period are displaye (in perc nt) showing
a stable distribution in both regards. In (B) the distribution of cancer cases by T-classifications divided int the different
periods are displayed. Nearly no difference could be detected between LD and PLD, whereas a higher proportion of T4
cancer could be seen during the PLD period in 2020 compared to the previous years. This effect is also reflected in the
UICC-classification (C) and UICC-subclassification (D) with more stage IV cancer during the PLD period in 2020 (50.79%
versus 59.18%). In (E) the time to intervention for the different time periods is displayed showing a trend towards a
shortened time to intervention during the 2020 LD period compared to previous years while the time in the 2020 PLD
period remained stable compared to previous years. In (F) time to intervention was further divided by diagnosis modality.
A shorter time to intervention by internal diagnosis during the LD period in 2020 was observed. * p < 0.05.
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3.2. Subgroup Analysis: Medical Department Mainz
The data analysis yielded a total of 160 cases that met the inclusion criteria. In 2018,
54 patients were found, 14 of whom could be assigned to the LD-E period and 40 patients to
the PLD-E period. In 2019 there were 25 patients in each period. In 2020, 20 patients could
be assigned to the LD period and 36 to the PLD period. The LD- to PLD-ratio was 25.93%
to 74.07% in 2018, 50% in each in 2019, and 35.71% to 64.29% in 2020. As such, there is no
obvious trend in 2020 compared to previous years in terms of patient number distribution.
Concerning the UICC classification, a trend towards a higher percentage of smaller
cancer stages was evident when comparing the LD period in 2020 to the reference years
2018 and 2019 (UICC I: 45% versus 28.21%). In 2020, just minor changes in UICC stadium
distributions were seen when compared to the PLD-E period in the reference years. The
subgroup analysis also found more patients with lower tumor stages (UICC I and II)
within the LD period in 2020 compared to the previous years. Interestingly, the time
to intervention (regardless of the type of intervention) in the 2020 LD period with an
average of 19.24 ± 993 days was lower than in the equivalent period of previous years
(22.97 ± 10.29 days). With 25.44 ± 11.39 days, the time to intervention in the PLD period
could be shown to be close to that of the previous years (26.90 ± 19.28 days). There
was a statistically significant difference in the time to intervention between the LD and
PLD period in 2020 (p = 0.04). Interestingly the time to intervention differed remarkably
between internal diagnosis and external diagnosis with a statistically significant shorter
time interval for internal diagnosis (14.17 ± 4.84 d vs. 26.88 ± 10.95 d) during LD 2020
(p = 0.013). Contrary, time to intervention for internal diagnosis increased again from LD
to PLD (p < 0.001, 14.17 ± 4.84 d vs. 25.13 ± 11.51 d). It is this large reduction in time to
intervention for internal diagnosis in LD 2020 that probably causes the significantly lower
time to intervention overall compared with the other periods, which remained relatively
stable in comparison with each other (Figure 2).
3.3. Subgroup Analysis: Medical Department Kiel
The analysis yielded a total of 167 cases that met the inclusion criteria. In 2018, there
were 64 cases in total, 30 in LD-E, 34 in the PLD-E period. In 2019, fewer patients were
initially diagnosed with oral carcinoma in the indicated periods (n = 47), and in 2020, 56
were diagnosed, including 21 in the LD period and 35 in the PLD. Here, the percentage of
patients in the 2020 LD period was lower than that within the other periods (2020: 37.5%,
2019: 42.55%, 2018: 46.88%). Compared with previous years, 2020 showed a significantly
higher proportion of stage IV carcinomas (50% versus 31.71%) in the LD period, while the
proportion of stage I carcinomas decreased significantly (18.75% versus 36.59%). In contrast,
the number of high tumor stages in the 2020 PLD period was similar to previous years
(51.72% versus 45.1%). Overall, there was no significant change in time to intervention in
the 2020 LD period compared with previous years (29.85 ± 11.67 d versus 30.49 ± 12.53 d)
while it was slightly, but not significantly, lower in the 2020 PLD period compared with 2018
and 2019 (26.65 ± 13.97 d versus 30.63 ± 11.25 d). Furthermore, no statistically significant
difference could be shown in time to intervention between internal and external diagnosis.
The time interval remained relatively stable between 25 and 35 days (Figure 3).
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ing a slight trend towards fewer cases during the LD period over years which, however, is not relevant for the comparison 
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are displayed. In the PLD-E period more T4 carcinomas were diagnosed, whereas the number of intermediate sized (T2, 
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Figure 3. Data sheet Medical Department Kiel: Distribution of patients with oral malignant lesions by different periods,
distribution of tumor stages (T-classificat on, UIC -clas ifi ion) and time to intervention during th different periods.
Abbreviations: LD—lockdown; PLD—post-lockdown; LD-E lockdown equivalent; PLD-E—post-lockdown equivalent;
UICC—Union international contre le cancer. In (A) cancer diagnoses per year and period are displayed (in percent) showing
a slight trend to ards fewer c ses during the LD period over y ars which, however, is not relevant for the comparison
of 2020 with previous years. In (B) the distribution of cancer cases by T-classifications divided into the different periods
are displayed. In the PLD-E period more T4 carcinomas were diagnosed, whereas the number of intermediate sized
(T2, T3) carcinomas showed reduced values compared to the LD period in 2020. The UICC-classification (C) and UICC-
subclassification (D) yielded interesting results. In 2020 a significantly higher proportion of stage IV carcinomas (50% versus
31.71%) in the LD period was observed, while the proportion of stage I carcinomas decreased significantly. Considering the
relatively stable results of the T-classification, this must indicate a higher rate of lymph nodes and distant metastases in the
population. In contrast, the number of high tumor stages in the 2020 PLD period was similar to previous years (51.72%
versus 45.1%). In (E) the time to intervention for the different time periods is displayed showing no significant change in
time to intervention in the 2020 LD period compared with previous years, while it was slightly, but not significantly, lower
in the 2020 PLD period compared with 2018 and 2019. In (F) time to intervention was further divided by diagnosis modality.
No statistically significant difference could be shown in time to intervention between internal and external diagnosis.
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3.4. Subgroup Analysis: Medical Department Berlin
The analysis for the medical department Berlin resulted in a total of 326 cases that met
the inclusion criteria. For 2018, a total of 110 cases were identified, of which 33 fell into the
LD-E period and 77 into the PLD-E period. A similar distribution was seen in subsequent
years, with a total of 113 first diagnosed oral cavity carcinomas in 2019 and 103 in 2020. The
distribution across the respective periods was relatively homogeneous at approximately
30–34% within the LD-E period and 66–70% during the PLD-E period with a slightly higher
proportion of patients in LD 2020 of 36.89%. Regarding the distribution of UICC stages,
there was a slightly higher proportion of high tumor stages in the LD period 2020 compared
to previous years (52.78% versus 47.89%), with this shift mainly due to a higher number of
initial diagnoses of stage III cancer. In contrast, the PLD period showed a significantly lower
proportion of diagnoses of higher tumor stages compared to previous years (54.1% versus
72.67%). Within the 2020 LD period, a slightly lower time to intervention was measurable
compared to previous years (23.06 ± 12.61 d versus 25.68 ± 16.7 d), whereas the data did
not differ in the PLD period (25.28 ± 14.52 d versus 25.00 ± 16.55 d). Within the PLD
period in 2020, the time to intervention for internal diagnosis was significantly lower than
that of the external diagnosis (p = 0.024; 22.38 ± 14.71 d vs. 30.81 ± 12.72 d). Although the
analysis was able to show quite homogeneously a shorter time to intervention within the
group of internal diagnoses, no other significant differences were found, possibly resulting
from a relatively high standard deviation arising from a small group size combined with a
great heterogeneity of the group (Figure 4).
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T4 carcino as decreased during the PLD period in 2020 compared to the previous years. This effect is also reflected in
the UICC-classification (C) and UICC-subclassification (D). In (E) the time to intervention for the different time periods is
displayed showing a slightly lower time to intervention during LD 2020. In (F), time to intervention was further divided by
diagnosis modality. Within the PLD period in 2020, the time to intervention for internal diagnosis was significantly lower
than that of the external diagnosis. * p < 0.05.
4. Discussion
The COVID-19 pandemic, now lasting for more than a year, is going to affect public
health and the entire society in the long-term. Efforts are made to lower the number
of people infected with Sars-CoV-19 while maintaining high-quality standards in the
treatment of other diseases. This relies on an efficient healthcare system adopting a
double strategy. Furthermore, not only the patient’s safety has to be guaranteed, but
also healthcare professionals have to be protected from the infection as they are both of
systemic importance and play a major role in limiting the spread of the disease. Given the
transmission mechanism via respiratory droplets [28], head and neck surgery has been
recognized as one of the specialties at the highest risk since the onset of the COVID-19
pandemic due to the invasive nature of examinations with patients not being able to wear
a mask and the aerosol-generating procedures like ultrasonic scaling. In a multicentric
survey (23 maxillofacial surgery departments) from Italy, 4% of maxillofacial residents
tested positive for SARS-CoV-2 [29]. Reports like this caused an energetic discussion
regarding the necessary measures to be taken in dental practices and clinics. During
the first pandemic wave, Germany and other countries put a general lockdown in place
more including the closure of dental offices in some federal states, such as Rhineland-
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Palatinate. On the other hand, a disproportional higher risk of being harmed by the
coronavirus of elderly patients and those with comorbid conditions is known. Reports
from China point to a higher risk for significant morbidity, including requirements for
ventilatory support with a hazard ratio of 3.56 for patients with cancer who acquired
COVID-19 [30]. What is more, cancer patients on active therapy require more interactions
with healthcare providers further increasing the risk of exposure to SARS-CoV-2 besides
a higher vulnerability due to oncologic treatments like surgery and especially radiation
and chemotherapy [3,31,32]. Another point to take into account is that cancer patients
are generally reported to be older and to have more comorbidities than the non-cancer
cohort [3]. To address the higher risk of cancer patients for both, exposure to SARS-CoV-
2 and a prolonged and severe coronavirus infection, the Infectious Diseases Working
Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO)
prepared a guideline on evidence-based management of COVID-19 in cancer patients. They
recommended to not delay/discontinue radiotherapy, targeted therapy, endocrine therapy
or surgery in patients without SARS-CoV-2 infection, whereas a delay/discontinuation
of chemotherapy and surgery were strongly recommended in patients with COVID-19
as chemotherapy was reported as a risk factor for severe COVID-19 and a perioperative
infection was associated with a higher mortality rate in patients treated by surgery [3].
The American Cancer Society estimated an amount of 5000 new cancer diagnoses per day
in 2021 in the US, which highlights the relevance of a well-structured healthcare system
during the pandemic to (1) balance the risk of a COVID-19 infection and the potential delay
in cancer diagnosis and treatment, and (2) manage the allocation of limited healthcare
resources during the healthcare crisis [31].
Zhang et al. reported a dramatic decrease in hospital visits to 6% compared to the
previous years in a hospital in Hangzhou (China). However, emergency visits were
increased 16-fold [33]. A multicentric survey performed 4 weeks after the pandemic started
in Italy reported of an 87% decrease in outpatient visits and surgery, a reduction in general
anesthesia surgery of 78% countrywide, whereas—although with a reduced incidence—the
surgical management of trauma and oncology have been carried out [29]. An overall
reduction of outpatient visits of 50% per week due to the measures implemented to contain
the pandemic was seen in a university medical center in Germany [34]. What is more, a
temporary interruption of private practice was observed in order to protect healthcare
workers and patients [29]. With dental offices reopening after the lockdown period, strict
protocols for patient triage and staff protection were implemented. Given that the pandemic
situation is still ongoing, these measures continue to be recommended, with economic and
public health consequences of massive extent. Preventive measures aim to slow down the
virus transmission via social distancing, hygiene, face masks, testing, isolation, and the
avoidance of public crowded places [35]. The following suggestions have been made for
the management of dental appointments: only patients with appointments should enter
the dental office; ideally, one patient is allowed to sit in the waiting room only. Patients
should not be accompanied unless necessary. Contact with a suspected/confirmed COVID-
19 person within 14 days or a positive test for COVID-19 should lead to a reschedule
of the appointment unless it is a dental emergency. Those patients should be treated
minimally invasive without aerosol-generating procedures if possible; airborne precautions
have to be added when this cannot be avoided. The university cancer center Hamburg
recommended to reschedule routine follow-ups of patients without active chemotherapy
until new symptoms are reported. Outpatient care of patients with active treatment should
be continued as planned. Here, especially radiotherapy of cancer patients in curative
intention should not be interrupted, whereas other radiation schedules should be reviewed
for their prioritization [34]. Tele-dentistry/medicine was suggested as an alternative for
face-to-face outpatient visits [35,36]. In consideration of these various measures, including
the closure/partial closure of dental offices during the lockdown in some federal German
states and the limitation to the treatment of dental emergencies, it would not be surprising
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to observe an increase in the number of oral malignant lesions after the lockdown period
compared to previous years.
In our study, the multicenter analysis showed no significant difference regarding initial
tumor diagnosis during LD and PLD compared to the previous years. Due to the relatively
limited number of patients, a reliable conclusion, especially retrospectively, was naturally
difficult, but there seems to be an absolute increase in early tumor stages (I and II) in the
PLD period in the medical department Mainz compared to the pooled mean of the previous
years. This could be attributed to an increased number of malignant transformations of
precursor lesions due to the delay in screening, which could eventually be a result of the
closure of dental practices within the LD in Rhineland-Palatinate, which did not occur in
the federal states of Kiel and Berlin. There, dental practices were allowed to treat patients
without any restrictions during LD. In accordance to this, the other medical departments
showed a trend towards a constant number of patients with a redistribution to the PLD
in Kiel and even a reduction in the total number of patients in Berlin with a constant
distribution to the different tumor stages compared to previous years.
On the one hand, the postponement of regular preventive examinations—especially in
patients with precursor lesions, but also in the regular care—could have led to a delay in the
diagnosis of malignant lesions; on the other hand, individual cases allow the assumption
that patients’ fear of infection also led to a delayed visit to the dentist, and thus higher
tumor stages may be observed after the lockdown than would normally be expected. In
this study, neither an overall increase in cancer diagnoses nor higher tumor stages could
be observed for the lockdown and the post-lockdown period compared to the previous
years. Contrary to the initial suggestions, time to treatment decreased during the lockdown
period (22.99 ± 12.72 d vs. 26.05 ± 13.84 d), presumably as a result of cancer diagnoses
being characterized as “essential surgery” that cannot be delayed. Furthermore, more
hospital staff have been available during the LD since elective surgeries were postponed.
Institutional protocols require the specification whether a surgical procedure will require
postoperative intensive care unit (ICU) admission (planned or inadvertent complications);
the decision to undertake such a procedure must be considered in conjunction with avail-
ability of ICU beds, therefore, a postponement of essential cancer surgery due to a lack of
ICU beds would not have been surprising. Overall, the limit of available ICU beds was not
reached, and beds were still available during the first LD in Germany.
The relationship between the time to treatment initiation and health outcomes has
extensively been explored. In a systematic review, Neal et al. summarized the effects of a
delayed treatment for different cancer entities, including oral cavity carcinoma, and found
a significant association between a shorter time to first diagnosis and a better treatment
outcome [37]. According to the data published by Goldsburry et al., the economic impact
of treatment delay in terms of healthcare cost weighted according to the distribution of
disease stage at treatment initiation showed an average increase in treatment costs of about
250% between stage I and stage IV of the diseases (according to the publication exemplified
by the tumor entities breast cancer, colorectal cancer, lung cancer and melanoma) [38].
Based on Australian data for four of the country’s most common cancers, Degeling et al.
developed an inverse stage-shift model to estimate the excess mortality and health eco-
nomic impact of delayed access to cancer services due to the COVID-19 pandemic and
found a calculative probability of progression from stage I to stage II in lung cancer for a
complete delay of 3 months of 8.3%. For a 6-month delay this probability was estimated
to be 16%. The model estimated that this would result in 11 and 43 excess deaths after
5 years within the population surveyed. The authors estimated an average increase in
healthcare costs, depending on the cancer entity, of up to AUD 36 million (6-months de-
lay) [18]. Sud et al. calculated an average loss of 0.97/2.19 live-years gained per patient for
a 3/6-month delay in cancer surgery in England. With 94 912 resections of major cancers
per year, this would result in 92 214/208 275 life-years lost due to the treatment delay [39].
Head and neck cancers are reported to be one of the fastest growing tumor entities with
an estimated doubling time of 99 days. On average, new metastases were detected after
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14.9 months leading to upstaging of the tumor. A 4.8% increase in tumor control risk
was estimated for a two-month treatment delay, whereas six months of delay are thought
to lead to an increase in risk of 6% [40]. In a large retrospective cohort study with over
37,000 patients included, Rygalski et al. showed that a surgical delay of longer than 67 days
independently increased the risk of death (hazard ratio 1.189). The authors suspected a
potential link between an increased time to intervention and the risk of distant metastases
as well as perineural and lymphovascular invasion and greater depth of invasion [41].
In consideration of those numbers, the dentists’ unique role as point of care facility for
patients with oral malignant lesions and as a system-relevant institution for early diagnosis
and therapy initiation becomes evident. Assuming that in about 8% of carcinomas there is a
progression from stage I to stage II within 3 months, there should be a mathematical excess
of 17 patients with a higher stage carcinoma in this study compared to the reference years.
However, since it is very unlikely that all patients analyzed within this study developed
oral malignant lesions right at the beginning of the lockdown and did not attend a medical
examination exactly over the period of 3 months, this effect will probably not have become
apparent in view of the relatively small group size in 2020 (213 patients).
Despite the observed level of compensation in the healthcare of patients with oral
malignant lesions in Germany within the analyzed periods, it is necessary to establish plans
for the future to ensure appropriate care of patients at risk. While maintaining hygiene
measures, individuals identified as high-risk patients (triage) should be encouraged to
adhere to a regular recall in order to detect malignant transformation of precursor lesions
at an early stage and initiate interventions. Close monitoring of patients with other risk
constellations (alcohol and nicotine consumption) should also be considered. In particular,
detailed information about the signs and symptoms of oral cavity carcinoma as well as
the necessary hygienic measures and the weighing of the corresponding risks are of great
importance. Here, telemedicine could also offer a substantial support for the education and
empowerment of the patient. In an extensive study that analyzed more than 2.5 million
social media posts, Moraliyage et al. found that the COVID-19 pandemic significantly
affected the emotional well-being of patients with cancer. The fears were mainly related to
the topics of therapy, mental health, diagnosis and continuation of therapy and concerned
the delay of diagnosis of diseases, an interruption of diagnostic procedures already started,
the postponement of cancer screening appointments, the lack of access to healthcare as
well as the delay of follow-up examinations [42]. A study on head and neck cancer patients
from Germany revealed that 40% were anxious regarding their disease but also in regard to
the psychological and physical consequences of the pandemic. Social isolation (prohibition
of visits) was reported to be a main problem (58.5%) [43–45].
The current pandemic and future similar scenarios demand the necessary restructuring
of the healthcare system in order to be able to take preventive measures and adequately
treat patients with malignant diseases even under difficult conditions and to keep the
number of infections as low as possible. This is also of great relevance from a health
economic point of view in light of the massive therapy costs, which will continue to rise in
the future due to individualized treatment regimens. The emotional impairment of patients
with cancer and the associated concerns about their care, which became clear in the study
by Moraliyage et al., show not only the structural requirements of risk-adapted healthcare
but also the relevance of emotional support for patients. The importance of digitalization
and especially telemedicine can be seen here. With the help of this, it may be possible
to inform patients at an early stage about signs and symptoms of malignant conditions
and the relevance of preventive examinations, the risk of transmitting infections and to
strengthen the patient in his or her self-care; if necessary, also to provide support from
other disciplines. Furthermore, oral cancer screenings performed by dentists play a crucial
role in the early detection of premalignant and malignant lesions in the oral cavity [46] and,
therefore, it should be notified for future epi- or pandemic settings that withholding dental
care has an impact on oral disease progression.
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Limitations of this study are the bias connected with the retrospective character of
the data collection (e.g., selection bias) as well a possible seasonal influence on hospital
admissions of patients with oral malignant lesions due to a fluctuation of surgeons or
references from external dentists which may vary over different periods. Another limitation
is the relatively small sample size of 653 patients in total and the regional limitation to three
medical centers in Germany that may not be representative for hospitals in other regions
and the German population as a whole. From a statistical point of view, the analytical
pathway with only few time points is statistically limitedly robust. By large, this study is
descriptive in nature and should be interpreted with caution.
5. Conclusions
Within these limitations and pooled over all three study centers, we found that the
incidence of oral malignant lesions did not increase in association with the COVID-19 2020
lockdown or the post lockdown period when compared to previous year. There was a
trend towards a shorter time to intervention during the lockdown period which in turn
supports the theory that the German healthcare system was still able to manage important
interventions adequately despite implemented restrictions. Notably, in the federal state
with the strictest lockdown implementation, Rhineland-Palatinate, there was an unusually
high number of low tumor stages in the post lockdown period compared to previous
years, possibly as primary practitioners had their practices closed, leading to a delayed
detection and referral, highlighting the relevance of primary dental care for early diagnosis
of premalignant and malignant lesions.
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